{"name":"Santen Pharmaceutical Co., Ltd.","slug":"santen-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"santen.com","description":"","hq":"Osaka","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"DE-117B Eye Drops","genericName":"DE-117B Eye Drops","slug":"de-117b-eye-drops","indication":"Glaucoma or ocular hypertension","status":"phase_3"},{"name":"DE-108","genericName":"DE-108","slug":"de-108","indication":"Glaucoma and ocular hypertension","status":"phase_3"},{"name":"DE-114 ophthalmic solution","genericName":"DE-114 ophthalmic solution","slug":"de-114-ophthalmic-solution","indication":"Glaucoma or ocular hypertension","status":"phase_3"},{"name":"Tafluprost ophthalmic solution 0.0015%","genericName":"Tafluprost ophthalmic solution 0.0015%","slug":"tafluprost-ophthalmic-solution-0-0015","indication":"Glaucoma, ocular hypertension","status":"phase_3"},{"name":"DE-111 ophthalmic solution","genericName":"DE-111 ophthalmic solution","slug":"de-111-ophthalmic-solution","indication":"Glaucoma or ocular hypertension","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"cardiovascular","drugs":[{"name":"STN1013800 ophthalmic solution","genericName":"STN1013800 ophthalmic solution","slug":"stn1013800-ophthalmic-solution","indication":"Treatment of non-infectious uveitis affecting the posterior segment of the eye","status":"phase_3"},{"name":"DE-089 ophthalmic solution","genericName":"DE-089 ophthalmic solution","slug":"de-089-ophthalmic-solution","indication":"Treatment of non-infectious uveitis affecting the posterior segment of the eye","status":"phase_2"},{"name":"DE-104 ophthalmic solution","genericName":"DE-104 ophthalmic solution","slug":"de-104-ophthalmic-solution","indication":"Treatment of non-infectious uveitis affecting the posterior segment of the eye","status":"phase_2"},{"name":"DE-117 ophthalmic solution high","genericName":"DE-117 ophthalmic solution high","slug":"de-117-ophthalmic-solution-high","indication":"Treatment of non-infectious uveitis affecting the posterior segment of the eye","status":"phase_2"},{"name":"STN1012600 ophthalmic solution 0.002%","genericName":"STN1012600 ophthalmic solution 0.002%","slug":"stn1012600-ophthalmic-solution-0-002","indication":"Treatment of non-infectious uveitis affecting the posterior segment of the eye","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"DE-127 Ophthalmic Solution low dose","genericName":"DE-127 Ophthalmic Solution low dose","slug":"de-127-ophthalmic-solution-low-dose","indication":"Other","status":"phase_2"},{"name":"DE-105 ophthalmic solution","genericName":"DE-105 ophthalmic solution","slug":"de-105-ophthalmic-solution","indication":"Other","status":"phase_2"},{"name":"DE-127 Ophthalmic Solution high dose","genericName":"DE-127 Ophthalmic Solution high dose","slug":"de-127-ophthalmic-solution-high-dose","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"DE-117B Eye Drops","genericName":"DE-117B Eye Drops","slug":"de-117b-eye-drops","phase":"phase_3","mechanism":"DE-117B is a selective rho kinase (ROCK) inhibitor that reduces intraocular pressure by improving aqueous humor outflow through the trabecular meshwork and Schlemm's canal.","indications":["Glaucoma or ocular hypertension"],"catalyst":""},{"name":"DE-108","genericName":"DE-108","slug":"de-108","phase":"phase_3","mechanism":"DE-108 is a small molecule that inhibits Rho-associated protein kinase (ROCK) to reduce intraocular pressure by decreasing aqueous humor outflow resistance.","indications":["Glaucoma and ocular hypertension"],"catalyst":""},{"name":"DE-114 ophthalmic solution","genericName":"DE-114 ophthalmic solution","slug":"de-114-ophthalmic-solution","phase":"phase_3","mechanism":"DE-114 is a selective rho kinase inhibitor that reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor.","indications":["Glaucoma or ocular hypertension"],"catalyst":""},{"name":"DE-127 Ophthalmic Solution low dose","genericName":"DE-127 Ophthalmic Solution low dose","slug":"de-127-ophthalmic-solution-low-dose","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"STN1013800 ophthalmic solution","genericName":"STN1013800 ophthalmic solution","slug":"stn1013800-ophthalmic-solution","phase":"phase_3","mechanism":"STN1013800 ophthalmic solution is a corticosteroid used to treat inflammation in the eye.","indications":["Treatment of non-infectious uveitis affecting the posterior segment of the eye"],"catalyst":""},{"name":"Tafluprost ophthalmic solution 0.0015%","genericName":"Tafluprost ophthalmic solution 0.0015%","slug":"tafluprost-ophthalmic-solution-0-0015","phase":"phase_3","mechanism":"Tafluprost is a prostaglandin F2α analogue that reduces intraocular pressure by increasing uveoscleral outflow.","indications":["Glaucoma, ocular hypertension"],"catalyst":""},{"name":"DE-089 ophthalmic solution","genericName":"DE-089 ophthalmic solution","slug":"de-089-ophthalmic-solution","phase":"phase_2","mechanism":"DE-089 ophthalmic solution is a corticosteroid used to treat inflammation in the eye.","indications":["Treatment of non-infectious uveitis affecting the posterior segment of the eye","Treatment of non-infectious keratitis and anterior uveitis"],"catalyst":""},{"name":"DE-104 ophthalmic solution","genericName":"DE-104 ophthalmic solution","slug":"de-104-ophthalmic-solution","phase":"phase_2","mechanism":"DE-104 ophthalmic solution is an anti-inflammatory agent that reduces inflammation in the eye.","indications":["Treatment of non-infectious uveitis affecting the posterior segment of the eye"],"catalyst":""},{"name":"DE-105 ophthalmic solution","genericName":"DE-105 ophthalmic solution","slug":"de-105-ophthalmic-solution","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DE-111 ophthalmic solution","genericName":"DE-111 ophthalmic solution","slug":"de-111-ophthalmic-solution","phase":"phase_3","mechanism":"DE-111 is a selective dopamine D1 receptor agonist that enhances aqueous humor outflow to reduce intraocular pressure in glaucoma.","indications":["Glaucoma or ocular hypertension"],"catalyst":""},{"name":"DE-117 ophthalmic solution high","genericName":"DE-117 ophthalmic solution high","slug":"de-117-ophthalmic-solution-high","phase":"phase_2","mechanism":"DE-117 ophthalmic solution high is an anti-inflammatory agent.","indications":["Treatment of non-infectious uveitis affecting the posterior segment of the eye"],"catalyst":""},{"name":"DE-127 Ophthalmic Solution high dose","genericName":"DE-127 Ophthalmic Solution high dose","slug":"de-127-ophthalmic-solution-high-dose","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"STN1012600 ophthalmic solution 0.002%","genericName":"STN1012600 ophthalmic solution 0.002%","slug":"stn1012600-ophthalmic-solution-0-002","phase":"phase_3","mechanism":"STN1012600 ophthalmic solution 0.002% is a corticosteroid used to reduce inflammation in the eye.","indications":["Treatment of non-infectious uveitis affecting the posterior segment of the eye"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-26","type":"pipeline","source":"simplywall.st","summary":"Why You Might Be Interested In Santen Pharmaceutical Co., Ltd. (TSE:4536) For Its Upcoming Dividend - simplywall.st","headline":"Why You Might Be Interested In Santen Pharmaceutical Co., Ltd. (TSE:4536) For Its Upcoming Dividend","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxONVpEUGR3R3JWdDhic2hSZkdTT2N0cU8zUVU5TjFrRmxFMFR3elJWSWduSVNkS0tnLUxSbVpIVi1MelhNSlh4cEM1YlplYTdqWWp4TnU1R0lDenJacFBXc215MnlxVlJIQkRjZC0yUWVuc2M4amdVd0pfSUk1MkEtQ1dPS2ZRZFNTU2IxX1NkWU9jQmctMHNDLVFqTE5FdE5fVW1zTFUtLW1nVDZ3VXJYS1FtWER6Qzg4d0M1UURSR3ZoTnRxVmVHV2ZOUTl0cU82dWduTzk2YjRrT0s3QWdOTQ?oc=5","date":"2026-03-26","type":"pipeline","source":"PharmiWeb.com","summary":"Faron Pharmaceuticals Ltd: Faron Appoints New CTO to Strengthen Late-Stage Development Activities - PharmiWeb.com","headline":"Faron Pharmaceuticals Ltd: Faron Appoints New CTO to Strengthen Late-Stage Development Activities","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPZjdGdjg2VUI5UVRfb0xfa3hmamhYVnlYV0o0UUUwQlk5OUZCbGV6SlhFZWgzeWhReEdNWVI2X0lkQ2Z5eWdlNjlSMkZHLVJHVVN2VEktWTJZLVNCeEo0c0Fadnl3d0tVVGFHV3ZIaWE0cy14V2ZDSkVaSHhtN1E3cnZFM1RRWFhEY2UyU0RfWGdKelBi?oc=5","date":"2026-01-08","type":"regulatory","source":"Yahoo Finance","summary":"RVL Pharmaceuticals Announces Santen Obtains Manufacturing and Marketing Approval in Japan for UPNEEQ® Mini Ophthalmic Solution 0.1% - Yahoo Finance","headline":"RVL Pharmaceuticals Announces Santen Obtains Manufacturing and Marketing Approval in Japan for UPNEEQ® Mini Ophthalmic S","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimgJBVV95cUxNd1gxZ0tUU0dxMkN2bjRNQVptQXBJODBXTEpsRklRMFc5TkVCN0lOUGM3SUh3eEFTakUwZGRJbW1vM2V2aEFoMGFXZFc1b181MWJoY054ckx3WGR6RzhnakhPTkVxeUF1bkZfXzd3YW53NFI5T0xyS2xlcFBvT1FJNXN4UVY4NXVLU1dnRHdGVFNocnVYaW92RkQtVmZjZWxra20yLXl3MFFFZnpWbG5LeDI0TWxNSWQyUjZUTUxqN0FOSER2bF9tQl81b19McE5nSGQ4VzRvc0pNbmttekxGVThZVjhSaEEwMHkyeHliRVZhU19IYXF1clFRdFZja2VfS0FwbHNqUWoycUU4YXBsZjVONmxhRlhhVVE?oc=5","date":"2025-08-18","type":"pipeline","source":"prnewswire.com","summary":"RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries - prnewswire.com","headline":"RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and A","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNUFNmREhVQ3FONm96VHlYQkJRcnJ4QWp2UlBwVTdmLVB2SFJ5WE1xUEp6N1RmZDkyZUFvckdPLUJXNVZ3LXc4N29NZ3RLNU5PUVNvMFJ4YzdUcmY1MzJSS1dLTTF3ZDVNS0UyZUhNNzJxSHRQNFQ3X0ZBN1F4RzBtdWlsWXJUdmRmZW00Zmw3TzAyaE80cUV4aTdLYTJ4UmRnaGtHMjZhVkZiZw?oc=5","date":"2023-07-25","type":"pipeline","source":"BioWorld News","summary":"Santen sells North American ophthalmic portfolio to Visiox, Harrow - BioWorld News","headline":"Santen sells North American ophthalmic portfolio to Visiox, Harrow","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNUi1rMjN2bTRYc2UySUVpZGJMZEtFVnlkOXcyVkRXVjh3dk1QTkZMZmh5RTFCMTYxYkh4OE5zaVpJZndTWDNzamlVS1V0NkR2X3pROC00WERGNXBrMF9sa0ExWnNLenB6MGs3MFo0R1JLTUJXaHRiUU0yaWNIaU5qWjBoMWI1N2NWSTdrVGplaTZOUUNIQkJKbzJfb1I?oc=5","date":"2023-07-19","type":"deal","source":"Eyes On Eyecare","summary":"Visiox Pharma acquires US rights to Omlonti - Eyes On Eyecare","headline":"Visiox Pharma acquires US rights to Omlonti","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxPUVFOTzM4X0hZS1cwWEZhbXVEbVlMa3J6NXV1OEFzQ2JTWFBLS19INnMwVWpSTldWSHBVcE9nSWhhcG5VM0JuZnhQeDVfNFJpOFRSQ2xMTGNwMGtwNjZJVENNeTY5X3pwOC1iTEdiQm9jZDFVaXFEV2FVR2N1OWpoaXBNVG5sajRhbTlPZnQ3ci01MllPWWk1OWJaaUE1MkFnVTY1bWt0bHdpT0cwMVRXZ3FYNFQ5SUFjR2RsWmQtY1cwQmRCM1h3Tm1YWHhsQTVST1NQUmtyMEI5ZE8zTUhUZHZiS3pNSVQyVmV3UnAxekNkVkxj?oc=5","date":"2023-07-18","type":"pipeline","source":"businesswire.com","summary":"Santen Agrees to Licensing Agreements and Asset Transfer for its Pharmaceutical Products in North America - businesswire.com","headline":"Santen Agrees to Licensing Agreements and Asset Transfer for its Pharmaceutical Products in North America","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOd2Jxd0l0LUNUZWNwWEZ5WHhqSkxtQmZTem43VVB3TTdwNHlVUGVKbkdmUmFVeVhVUl84bjhDTW1YUFJDMXNzWjkzUFlmTWJtcmwyOXRWdHNhLVBaRHFoTmN0UUN4ajgxYkJtNURjYlRRaVREem1PT0hQYTQyWEI4SUZMVE14YkVtYVFqbjUzMWJDdkYyNWltSldEdlpWOXdGZUQxbTQ4R1JqOXc?oc=5","date":"2023-07-18","type":"deal","source":"Ophthalmology Times","summary":"Harrow acquires Santen’s branded ophthalmic portfolio - Ophthalmology Times","headline":"Harrow acquires Santen’s branded ophthalmic portfolio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE1yZTFRN2tFZzNzaDNBOHhuMUlRTy1HcXJMZnFESlIzSXZZWUtpZFJzLUlEWERTSTdrWlJvd1c3ei00bmpoaU1HY0wzSHBEbXhqQnVJLUNDWnhiV3lBbGZHcURibDVRNVp3VmNkeEF5VXFXbHUt?oc=5","date":"2023-01-18","type":"pipeline","source":"pwc.com","summary":"A conversation with Santen’s CIO: What does an IT organisation need to survive and win in the global market? (Part 2) - pwc.com","headline":"A conversation with Santen’s CIO: What does an IT organisation need to survive and win in the global market? (Part 2)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOR2FrUWcyN09LbkY1TG5Pc0pVdUhfTWNvYTJSOHhBQWdiemlISVNpeEFWdDJpc0M2RnJqUm9malF6YUVVX3laSGZFY1BOMTFBcVJFTi0wNTlPSXJQVW9ETVZhWE5kTE9UTWhmR1Y5M1lGNWJ0U2JYZWxGSjZfT0hhMFVkT245YTVHUkgtZWRrTENWRGZEX0FndlJEQlJqdWQx?oc=5","date":"2020-09-17","type":"pipeline","source":"Dallas Innovates","summary":"Fort Worth Ophthalmic Biotech Eyevance Exits to Japanese Firm for $225M - Dallas Innovates","headline":"Fort Worth Ophthalmic Biotech Eyevance Exits to Japanese Firm for $225M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxNN2VpdGwwSkp6TWpJdkQ1WFpSM0xySDVOT1FGelVPNWxTajBZNnVPdlZVUURRWXQzY19sNmY1aUlpb3JHSHBUOGtBbGZrbzl0WDB4VUE4NUhHV2NmeGxOS3lVYXFGM2ZkUTVRNDdhNFM1UW01RExUdTNuc0pJY3oxc1JLcTdQejJyYzhxWWY0Q044RnhfZXpVV2M4QVdrV09MQTVTVXc2QUZTWk5PZWZoYktsU3BWeDFtLUlhTlZ0cTlmcmktSGpDa0dQSUFPdw?oc=5","date":"2020-09-16","type":"pipeline","source":"prnewswire.com","summary":"Santen and U.S. Ophthalmic Company Eyevance Enter into Share Purchase Agreement - prnewswire.com","headline":"Santen and U.S. Ophthalmic Company Eyevance Enter into Share Purchase Agreement","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2020-07-28","type":"pipeline","source":"GlobeNewswire","summary":"Santen and RVL Pharmaceuticals, Inc., an Osmotica Company, - GlobeNewswire","headline":"Santen and RVL Pharmaceuticals, Inc., an Osmotica Company,","sentiment":"neutral"}],"patents":[],"drugCount":13,"phaseCounts":{"phase_3":7,"phase_2":6},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}